THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
发明人:
OLSON, ERIC N.,LONG, CHENGZU,MCANALLY, JOHN R.,SHELTON, JOHN M.,BASSEL-DUBY, RHONDA
申请号：
CA2959130
公开号：
CA2959130A1
申请日:
2015.08.11
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by mutations in the gene encoding dystrophin, a protein required for muscle fiber integrity. The disclosure reports CRISPR/Cas9-mediated gene editing (Myo-editing) is effective at correcting the dystrophin gene mutation in the mdx mice, a model for DMD. Further, the disclosure reports optimization of germline editing of mdx mice by engineering the permanent skipping of mutant exon (exon 23) and extending exon skipping to also correct the disease by post-natal delivery of adeno-associate virus (AAV). AAV-mediated Myo-editing can efficiently rescue the reading frame of dystrophin in mdx mice in vivo. The disclosure reports means of Myo-editing-mediated exon skipping has been successfully advanced from somatic tissues in mice to human DMD patients-derived iPSCs (induced pluripotent stem cells). Custom Myo-editing was performed on iPSCs from patients with differing mutations and successfully restored dystrophin protein expression for all mutations in iPSCs-derived cardiomyocytes.
